Cytokinetics CYTK Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's accounts payable?
- Cytokinetics (CYTK) reported accounts payable of $24.71M in Q1 2026.
- How has Cytokinetics's accounts payable changed year-over-year?
- Cytokinetics's accounts payable increased by 77.2% year-over-year, from $13.94M to $24.71M.
- What is the long-term trend for Cytokinetics's accounts payable?
- Over 5 years (2020 to 2025), Cytokinetics's accounts payable has grown at a 22.6% compound annual growth rate (CAGR), from $8.05M to $22.34M.
- What does accounts payable mean?
- Money the company owes to its suppliers for goods or services already received.
- How do you interpret accounts payable?
- An increase may suggest improved cash flow management or delayed payments, while a decrease may indicate faster settlement of obligations.
- How does accounts payable compare across companies?
- Standard across all industries; biotech firms typically maintain lean payables relative to R&D spend.